References from scientific journals

Acebutolol.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 1985 Jul 5;27(691):58-60. Med Lett Drugs Ther. 1985. PMID: 3892259 Clinical Trial. No abstract available.


Acebutolol: ten years of experience.

De Bono G, Kaye CM, Roland E, Summers AJ. De Bono G, et al. Am Heart J. 1985 May;109(5 Pt 2):1211-3. doi: 10.1016/0002-8703(85)90712-4. Am Heart J. 1985. PMID: 2859785 Review.

Acebutolol is cardioselective, and clinical use has borne out the low incidence of bronchospasm in patients with impaired lung function. ...A combination of selectivity and ISA may be responsible for the low incidence of tiredness and cold extremities observed with aceb …
Acebutolol is cardioselective, and clinical use has borne out the low incidence of bronchospasm in patients with impaired lung functi …

A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production.

Muta K, Fukami T, Nakajima M. Muta K, et al. Biochem Pharmacol. 2015 Dec 15;98(4):659-70. doi: 10.1016/j.bcp.2015.09.016. Epub 2015 Sep 25. Biochem Pharmacol. 2015. PMID: 26408002

Acebutolol, a beta-adrenergic receptor-blocker, occasionally causes drug-induced lupus erythematosus (DILE). Acebutolol is mainly metabolized to diacetolol. Because metabolic activation has been considered to be related to acebutolol-induced toxicity, we soug …
Acebutolol, a beta-adrenergic receptor-blocker, occasionally causes drug-induced lupus erythematosus (DILE). Acebutolol is mai …

A case of fatal acebutolol poisoning: an illustration of the potential of molecular networking.

Le Daré B, Allard S, Bouvet R, Baert A, Allard PM, Morel I, Gicquel T. Le Daré B, et al. Int J Legal Med. 2020 Jan;134(1):251-256. doi: 10.1007/s00414-019-02062-9. Epub 2019 Apr 17. Int J Legal Med. 2020. PMID: 30997571

However, acebutolol's beta-blocking properties also extend the QRS and QTc intervals, and may predispose the patient to ventricular tachydysrhythmia. ...A molecular networking approach provided useful information on acebutolol's metabolism and revealed …
However, acebutolol's beta-blocking properties also extend the QRS and QTc intervals, and may predispose the patient to ventri …

[Sectral].

de Roquefeuil F, Goupil C. de Roquefeuil F, et al. Soins Cardiol. 1985 Mar;(25):I-II. Soins Cardiol. 1985. PMID: 3847165 French. No abstract available.


Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration.

Abernethy DR, Arendt RM, Greenblatt DJ. Abernethy DR, et al. Am Heart J. 1985 May;109(5 Pt 2):1120-5. doi: 10.1016/0002-8703(85)90695-7. Am Heart J. 1985. PMID: 2859774

The latter property may not be significant at clinically used doses. Acebutolol has both antihypertensive and antiarrhythmic effects. As with beta blockers in general, the antihypertensive mechanism of acebutolol is not known. ...The pharmacologic profile of diaceto …
The latter property may not be significant at clinically used doses. Acebutolol has both antihypertensive and antiarrhythmic effects. …

Infantile haemangioma and β-blockers in otolaryngology.

Leboulanger N, Cox A, Garabedian EN, Denoyelle F. Leboulanger N, et al. Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Nov;128(5):236-40. doi: 10.1016/j.anorl.2010.11.009. Epub 2011 Apr 16. Eur Ann Otorhinolaryngol Head Neck Dis. 2011. PMID: 21498145 Free article. Review.


Effects of acebutolol on the serum lipid profile.

Clucas A, Miller N. Clucas A, et al. Drugs. 1988;36 Suppl 2:41-50. doi: 10.2165/00003495-198800362-00008. Drugs. 1988. PMID: 3063505 Review.

The results indicate that, on average, acebutolol does not have any adverse effects on plasma lipids and may even reduce total and low density lipoprotein (LDL)-cholesterol by 7 and 5%, respectively. In contrast, the other beta-blockers compared under the same conditions ( …
The results indicate that, on average, acebutolol does not have any adverse effects on plasma lipids and may even reduce total and lo …

Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.

Singh BN, Thoden WR, Wahl J. Singh BN, et al. Pharmacotherapy. 1986 Mar-Apr;6(2):45-63. doi: 10.1002/j.1875-9114.1986.tb03451.x. Pharmacotherapy. 1986. PMID: 3012486 Review.

Acebutolol is a new hydrophilic, cardioselective beta-adrenergic-blocking agent that possesses partial agonist and membrane-stabilizing activities. ...Controlled clinical trials documented the antianginal actions of oral acebutolol in chronic stable angina pectoris; …
Acebutolol is a new hydrophilic, cardioselective beta-adrenergic-blocking agent that possesses partial agonist and membrane-stabilizi …

Clinical pharmacology of acebutolol.

Ryan JR. Ryan JR. Am Heart J. 1985 May;109(5 Pt 2):1131-6. doi: 10.1016/0002-8703(85)90697-0. Am Heart J. 1985. PMID: 2859776

The clinical pharmacology and pharmacokinetics of acebutolol are summarized. Acebutolol and its longer-acting metabolite, diacetolol, are rapidly absorbed into the circulation from the gastrointestinal tract, and their bioavailability, unlike that of propranolol and …
The clinical pharmacology and pharmacokinetics of acebutolol are summarized. Acebutolol and its longer-acting metabolite, diac …